TNGX insider trading
HealthcareTango Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Company website: www.tangotx.com
TNGX insider activity at a glance
FilingIQ tracks 150 insider transactions for TNGX in filings since Oct 6, 2022. The most recent transaction is dated Oct 1, 2026.
Across the full history, 14 open-market purchases
and 84 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TNGX insider trades is 55.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TNGX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding TNGX
Frequently asked
- How many insider trades does FilingIQ track for TNGX?
- FilingIQ tracks 150 Form 4 insider transactions for TNGX (Tango Therapeutics, Inc.), covering filings from Oct 6, 2022 onwards. 11 of those are dated within the last 90 days.
- Are TNGX insiders net buyers or net sellers?
- Across the full Form 4 history for TNGX, 14 transactions (9%) were open-market purchases and 84 (56%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TNGX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is TNGX in?
- Tango Therapeutics, Inc. (TNGX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.72B.
Methodology & sources
Every TNGX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.